Trial Profile
A phase III multicentre randomised clinical trial comparing rituximab with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms R-CHOP 14 vs 21
- 13 Mar 2020 Results comparing International prognostic indices in diffuse large B-cell lymphoma using different trials published in the Blood
- 01 Oct 2017 Results of a analysis assessing CNS relapse fro patients published in the Annals of Oncology
- 28 May 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.